

CLAIMS

1. Crystalline methyl $\{(2S)-1-[(2S,5S)-2-(9-\{2-[(2S,4S)-1-\{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl\}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl\}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl\} carbamate phosphate (Compound I Phosphate Form VIII) characterized by an X-ray powder diffractogram comprising the following peaks: $4.2, 8.3, \text{ and } 16.0^\circ 2\theta \pm 0.2^\circ 2\theta$, as determined on a diffractometer using Cu-K α radiation at a wavelength of 1.5406 Å.$
2. Compound I Phosphate Form VIII according to claim 1, wherein the diffractogram further comprises peaks at $10.1, 11.5, \text{ and } 13.1^\circ 2\theta \pm 0.2^\circ 2\theta$.
3. Compound I Phosphate Form VIII according to claim 1, wherein the diffractogram is substantially as shown in Figure 21.
4. Compound I Phosphate Form VIII according to claim 1, characterized by a differential scanning calorimetry (DSC) curve that comprises an endotherm at about 181 °C.
5. Compound I Phosphate Form VIII according to claim 4, wherein the DSC curve is substantially as shown in Figure 22.
6. Crystalline methyl $\{(2S)-1-[(2S,5S)-2-(9-\{2-[(2S,4S)-1-\{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl\}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl\}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl\} carbamate phosphate (Compound I Phosphate Form IX) characterized by an X-ray powder diffractogram comprising the following peaks: $8.4, 16.1, \text{ and } 16.3^\circ 2\theta \pm 0.2^\circ 2\theta$, as determined on a diffractometer using Cu-K α radiation at a wavelength of 1.5406 Å.$

7. Compound I Phosphate Form IX according to claim 6, wherein the diffractogram further comprises peaks at 10.2, 20.5, and $21.7^{\circ}2\theta \pm 0.2^{\circ}2\theta$.
8. Compound I Phosphate Form IX according to claim 6, wherein the diffractogram is substantially as shown in Figure 24.
9. Compound I Phosphate Form IX according to claim 6, characterized by a differential scanning calorimetry (DSC) curve that comprises an endotherm at about 177 °C and an endotherm at about 204 °C.
10. Compound I Phosphate Form IX according to claim 9, wherein the DSC curve is substantially as shown in Figure 25.
11. Crystalline methyl $\{(2S)-1-[(2S,5S)-2-(9-\{2-[(2S,4S)-1-[(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl]-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl\}carbamate$ phosphate (Compound I Phosphate Form XI) characterized by an X-ray powder diffractogram comprising the following peaks: 8.9, 13.1, and $18.1^{\circ}2\theta \pm 0.2^{\circ}2\theta$, as determined on a diffractometer using Cu-K α radiation at a wavelength of 1.5406 Å.
12. Compound I Phosphate Form XI according to claim 11, wherein the diffractogram further comprises peaks at 4.0 and $17.5^{\circ}2\theta \pm 0.2^{\circ}2\theta$.
13. Compound I Phosphate Form XI according to claim 11, wherein the diffractogram is substantially as shown in Figure 28.
14. Compound I Phosphate Form XI according to claim 11, characterized by a differential scanning calorimetry (DSC) curve that comprises an endotherm at about 172 °C and an endotherm at about 198 °C.

15. Compound I Phosphate Form XI according to claim 14, wherein the DSC curve is substantially as shown in Figure 29.
16. Crystalline methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-[(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl]-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate phosphate (Compound I Phosphate Form XII) characterized by an X-ray powder diffractogram comprising the following peaks: $3.8, 7.5, \text{ and } 16.9^\circ 2\theta \pm 0.2^\circ 2\theta$, as determined on a diffractometer using Cu-K α radiation at a wavelength of 1.5406 Å.
17. Compound I Phosphate Form XII according to claim 16, wherein the diffractogram further comprises peaks at $8.5, 10.0, \text{ and } 12.4^\circ 2\theta \pm 0.2^\circ 2\theta$.
18. Compound I Phosphate Form XII according to claim 16, wherein the diffractogram is substantially as shown in Figure 31.
19. Compound I Phosphate Form XII according to claim 16, characterized by a differential scanning calorimetry (DSC) curve that comprises an endotherm at about 205 °C and an endotherm at about 229 °C.
20. Compound I Phosphate Form XII according to claim 16, wherein the DSC curve is substantially as shown in Figure 32.